EGFR and cancer: The main function of anti-EGFR MoAbs is to compete with endogenous ligands for binding to EGFR, thereby blocking downstream RAS and MAPK signaling pathways, inhibiting proliferation of cancer cells, and prolonging the survival of patients with advanced cancer (3).